Safety and Effectiveness of World Health Organization Dosing Guidelines of Lopinavir/Ritonavir for Children

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT01172535
First received: July 28, 2010
Last updated: July 7, 2014
Last verified: July 2014

July 28, 2010
July 7, 2014
November 2010
July 2013   (final data collection date for primary outcome measure)
  • Safety, as determined by non-occurrence of any recurring Grade 3 or non-life-threatening Grade 4 toxicity, or a single life-threatening Grade 4 toxicity [ Time Frame: Measured at study completion ] [ Designated as safety issue: Yes ]
  • Area under the curve (AUC), as determined by a non-compartmental analysis of 12-hour pharmacokinetic sampling for lopinavir/ritonavir [ Time Frame: Measured after 4 weeks of treatment ] [ Designated as safety issue: No ]
  • Maximum and minimum concentrations and half-life of lopinavir/ritonavir [ Time Frame: Measured at study completion ] [ Designated as safety issue: No ]
  • Proportion of participants with an AUC of less than 10% of adults [ Time Frame: Measured after 4 weeks of treatment ] [ Designated as safety issue: No ]
  • Number and percent of participants experiencing adverse events of Grade 3 or greater [ Time Frame: Measured at study completion ] [ Designated as safety issue: Yes ]
  • Adherence, defined as proportion of doses taken [ Time Frame: Measured at study completion ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01172535 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Safety and Effectiveness of World Health Organization Dosing Guidelines of Lopinavir/Ritonavir for Children
A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines

Treatment of children and infants with HIV requires modification of medication dosing according to a child's specific weight. For lopinavir/ritonavir (LPV/r), a second line treatment option that is increasingly necessary due to infant drug resistance, this dosing is often complicated and impractical in busy clinical settings. To address this, the World Health Organization (WHO) has released a simplified dosing table based on infant weight bands. This study will evaluate the absorption, safety, and tolerance of LPV/r in infants when dosed according to the new WHO guidelines.

Because of previous exposure to nevirapine or other non-nucleoside reverse transcriptase inhibitors (NNRTIs), either by direct treatment or through their mothers in pregnancy, infants must often receive an alternate antiretroviral regimen that includes LPV/r. Dosing of LPV/r is currently based on a child's specific weight, and calculations of proper dosages are often too complicated to be practical in busy clinics, particularly those in limited resource settings. In order to simplify medication delivery and reduce prescribing errors, the WHO has released a dosing schedule for LPV/r based on groupings of infants by weight. This study will evaluate the pharmacokinetics, safety, and tolerance of LPV/r dosed according to these guidelines.

Participation in this study will last 6 months. Infant participants and their caretakers will need to attend study visits at entry and Weeks 2, 4, 12, and 24. At entry, participants will be given LPV/r either in liquid or tablet form, depending on whether the infant can swallow pills. Dosing will be calculated using the WHO schedule. At all study visits, infant participants will undergo a physical exam and caretakers will be asked about how well the child is taking the study medications. In addition, at Weeks 4, 12, and 24, blood samples will be taken from the infant to determine health and levels of the medication in the body. The visit on Week 4 will also require pharmacokinetic testing, which means the child will need to be monitored at the hospital for 12 hours and complete six additional blood drawls. All other study visits will last 1 to 2 hours.

Interventional
Phase 2
Phase 3
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV
Drug: Lopinavir/ritonavir
Heat-stable tablets of 100 mg lopinavir, 25 mg ritonavir, or liquid formulation of 80 mg lopinavir, 20 mg ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines
Other Names:
  • Kaletra
  • LPV/r
Experimental: Lopinavir/ritonavir
Participants will receive lopinavir/ritonavir in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.
Intervention: Drug: Lopinavir/ritonavir
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
97
December 2013
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Weight equal to or greater than 3 kg, but less than 25 kg, at the time of enrollment
  • Confirmed diagnosis of HIV-1 infection
  • Lopinavir/ritonavir (LPV/r)-treatment naïve and LPV/r-treatment eligible as defined by country-specific guidelines or the WHO pediatric treatment guidelines and confirmed by investigator
  • Willingness to take two nucleoside reverse transcriptase inhibitos (NRTIs), in accordance with appropriate national or international treatment guidelines
  • Demonstrated ability and willingness to swallow tablets for children larger than 10 kg. This can be assessed before inclusion (for example, a test trial with similar size solid tablet such as tic-tac).
  • Participants in the weight band between 10 and 16.9 kg that are unable to swallow tablets will receive liquid formulation
  • Parent or legal guardian able and willing to provide written informed consent

Exclusion Criteria:

  • Planned concurrent use of non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors, or an entry inhibitor
  • Planned concurrent protease inhibitor (PI) use, other than LPV/r
  • Prior treatment with LPV/r. Prior treatment with other PIs is allowed.
  • Results of certain laboratory tests indicating adverse events of Grade 3 or greater
  • Results of a lipase test indicating adverse event of Grade 2 or greater or clinical evidence of pancreatitis within 30 days prior to study entry
  • Tuberculosis co-treatment with rifampicin-containing regimen
  • Treatment with any enzyme-inducing antiepileptic drugs, such as henobarbital, phenytoin or carbamazepine
  • Clinical condition requiring the use of a prohibited medication (see protocol for more details)
  • Clinically unstable child requiring acute treatment for a serious opportunistic infection
  • Chemotherapy for active malignancy
  • Any clinically significant diseases (other than HIV-1 infection) or clinically significant findings during the screening medical history or physical examination that, in the investigator's opinion, would compromise participation in this study
  • Treatment with experimental drugs for any indication within 30 days prior to study entry
  • Known history of cardiac conduction abnormality and/or underlying structural heart disease, including congenital long QT
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States,   Brazil,   South Africa,   Thailand
 
NCT01172535
P1083, 10787, IMPAACT P1083
Yes
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Study Chair: Jorge A. Pinto, MD Federal University of Minas Gerais
National Institute of Allergy and Infectious Diseases (NIAID)
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP